Just months after licensing EvaMist from Vivus, KV Pharmaceutical announced that the FDA has approved the therapy for the treatment of menopausal symptoms. Vivus is positioned to earn a $140 million milestone payday on approval along with two sizeable milestones for sales goals. Shares of Vivus were buoyed by the news.
- see the release
- check out the AP report on the approval
Related Article:
Vivus shares buoyed by late-stage Evamist data. Report